099430.KQ BioPlus Co. Ltd.
- Market cap
- KRW 197B
- P/E
- 15.2x
- P/B
- 1.10x
- ROE
- 9.8%
- Dividend yield
- 2.19%
- Fundamental score
- 2.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 099430.KQ undervalued?
Graham number099430.KQ trades 13.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioPlus Co. Ltd. fundamental analysis
10 of 22 checks passedROE 0/2
Low return on equity (9.8%), below 10%.
ROA 1/1
Return on assets (5.9%) is above the industry median (3.4%).
Profit Consistency 2/2
Profitable for 8 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-3.0%) is not above the 5-year average (6.9% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-3.0%) is below the industry median (6.6%).
Revenue Growth 2/2
Revenue grew 17.0% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (7.6%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 79.8x against interest expense, well covered.
PE vs Market 0/1
PE (15.2x) is above the market median (11.3x).
PE vs Industry 1/1
PE (15.2x) is below the industry median (19.4x).
PBV 0/1
Price to book (1.1x) is above the industry median (0.8x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 16.7, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 2.19, above 1.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
BioPlus Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioPlus Co. Ltd.
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus " Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy pr…
Full company profileBioPlus Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioPlus Co. Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 11.0B | 17.0B | 24.4B | 37.4B | 56.7B | 65.0B | 66.4B | 90.9B | 104B |
| Gross Profit | 6.66B | 11.2B | 16.6B | 23.6B | 33.8B | 39.6B | 42.6B | 60.6B | 71.3B |
| Operating Income | 3.97B | 6.80B | 12.3B | 16.7B | 25.2B | 28.0B | 23.7B | 15.0B | 23.8B |
| EBITDA | - | - | - | - | 29.4B | 35.3B | 21.2B | 21.9B | 28.4B |
| Net Income | 2.33B | 5.62B | 9.70B | 10.7B | 21.1B | 25.6B | 14.2B | 15.0B | 17.4B |
| EPS | 42 | 101 | 174 | 190 | 365 | 447 | 251 | 244 | 283 |
| Balance Sheet | |||||||||
| Total Assets | 13.3B | 21.0B | 37.9B | 88.5B | 147B | 173B | 264B | 285B | 297B |
| Total Liabilities | 5.91B | 3.15B | 9.42B | 9.76B | 33.3B | 34.7B | 117B | 90.1B | 96.3B |
| Shareholders' Equity | 7.37B | 17.8B | 28.5B | 78.7B | 113B | 128B | 133B | 175B | 178B |
| Cash & Short-term Investments | 4.48B | 2.85B | 16.0B | 41.0B | 79.0B | 65.0B | 41.7B | 21.1B | 20.2B |
| Total Debt | - | 45.8M | 38.1M | - | - | - | - | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | 3.15B | 4.96B | 10.0B | 13.4B | 13.4B | 16.0B | 22.3B | 14.7B | 13.5B |
| Capital Expenditure | 736M | 6.51B | 1.10B | 15.4B | 6.69B | 21.6B | 96.6B | 47.9B | 10.1B |
| Free Cash Flow | - | 354M | 8.95B | -2.01B | 6.67B | -5.53B | -74.4B | -33.2B | 3.32B |
| Ratios | |||||||||
| ROE | 31.6% | 31.5% | 34.0% | 13.6% | 18.7% | 20.0% | 10.6% | 8.6% | 9.8% |
| ROA | 17.5% | 26.8% | 25.6% | 12.1% | 14.4% | 14.8% | 5.4% | 5.3% | 5.9% |
| Net Profit Margin | 21.1% | 33.0% | 39.8% | 28.5% | 37.3% | 39.3% | 21.3% | 16.5% | 16.8% |
| Debt to Equity | - | 0.00x | 0.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioPlus Co. Ltd. dividends
- Dividend yield
- 2.19%
- Forward dividend
- 70.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Dec 29, 2025
Last stock split: 4:1 on Nov 23, 2022.
Who owns BioPlus Co. Ltd.
- Insiders 29.83%
- Institutions 1.51%
- Public & others 68.67%
- Shares outstanding 61.5M
- Free float 43.0M
BioPlus Co. Ltd. company profile
- Company name
- BioPlus Co. Ltd.
- Ticker
- 099430.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 161
- Fiscal year end
- December
- Address
- Seongnam Woolim Lions Valley 2 cha A dong 1801 and 1802 ho, Seongnam-si, South Korea
- Phone
- 82 3 1742 1898
- Website
- bioplus.co.kr
About BioPlus Co. Ltd.
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus " Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; Slim Slimmer, a lipolysis solution; LumiDew, a whitening solution; JuveniHill, an anti-wrinkle solution; and hair scalp care, hair treatment, hair nutrition solutions under the BelloHa and BellaChe names, as well as cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name. The company was founded in 2003 and is based in Seongnam-si, South Korea.
BioPlus Co. Ltd. management
1- Hyun-Kyu JungChief Executive Officer